0.6558
price down icon20.02%   -0.1642
after-market アフターアワーズ: .66 0.0042 +0.64%
loading
前日終値:
$0.82
開ける:
$0.78
24時間の取引高:
13.52M
Relative Volume:
2.37
時価総額:
$195.50M
収益:
$52.29M
当期純損益:
$-134.84M
株価収益率:
-0.8744
EPS:
-0.75
ネットキャッシュフロー:
$-117.11M
1週間 パフォーマンス:
-24.62%
1か月 パフォーマンス:
-35.71%
6か月 パフォーマンス:
-24.28%
1年 パフォーマンス:
-2.15%
1日の値動き範囲:
Value
$0.6397
$0.79
1週間の範囲:
Value
$0.6397
$0.88
52週間の値動き範囲:
Value
$0.304
$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
名前
Sangamo Therapeutics Inc
Name
セクター
Healthcare (1164)
Name
電話
(510) 970-6000
Name
住所
501 CANAL BLVD., RICHMOND, CA
Name
職員
0
Name
Twitter
@sangamotx
Name
次回の収益日
2025-03-17
Name
最新のSEC提出書
Name
SGMO's Discussions on Twitter

SGMO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SGMO
Sangamo Therapeutics Inc
0.6558 195.50M 52.29M -134.84M -117.11M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-13 アップグレード Truist Hold → Buy
2024-12-10 繰り返されました H.C. Wainwright Buy
2023-11-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-04-28 ダウングレード BofA Securities Neutral → Underperform
2023-02-27 アップグレード Wedbush Neutral → Outperform
2023-01-06 ダウングレード BofA Securities Buy → Neutral
2022-06-13 再開されました Wedbush Neutral
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-01-07 再開されました Guggenheim Neutral
2021-01-06 開始されました Stifel Hold
2020-12-16 再開されました H.C. Wainwright Buy
2020-09-08 開始されました BofA Securities Buy
2020-07-07 開始されました SunTrust Buy
2019-08-26 開始されました H.C. Wainwright Buy
2018-11-14 ダウングレード JP Morgan Overweight → Neutral
2018-11-09 ダウングレード Guggenheim Buy → Neutral
2018-10-10 開始されました Guggenheim Buy
2018-06-20 開始されました BofA/Merrill Buy
2017-11-15 アップグレード Piper Jaffray Neutral → Overweight
2017-06-22 再開されました Jefferies Buy
2016-11-01 ダウングレード Wedbush Outperform → Neutral
2016-10-19 ダウングレード Piper Jaffray Overweight → Neutral
2015-12-04 開始されました Wells Fargo Outperform
2015-10-23 再開されました Jefferies Buy
2013-05-03 開始されました BioLogic Equity Research Sell
2011-02-23 繰り返されました JMP Securities Mkt Outperform
2010-07-29 繰り返されました Wedbush Outperform
2009-10-19 開始されました Brean Murray Sell
2009-10-07 繰り返されました Leerink Swann Outperform
2009-08-25 繰り返されました JMP Securities Mkt Outperform
すべてを表示

Sangamo Therapeutics Inc (SGMO) 最新ニュース

pulisher
02:49 AM

Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com

02:49 AM
pulisher
Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart

Mar 20, 2025
pulisher
Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: - openPR

Mar 20, 2025
pulisher
Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener

Mar 19, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa

Mar 18, 2025
pulisher
Mar 18, 2025

8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus.com

Mar 18, 2025
pulisher
Mar 18, 2025

Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 17, 2025

Sangamo: Q4 Earnings Snapshot - mySA

Mar 17, 2025
pulisher
Mar 17, 2025

Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics Q4 2024 Earnings: EPS of -$0.11 Misses Esti - GuruFocus.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo: Q4 Earnings Snapshot -March 17, 2025 at 04:36 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics shares fall as Q4 results miss estimates By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics shares fall as Q4 results miss estimates - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

SANGAMO THERAPEUTICS, INC SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics earnings missed, revenue fell short of estimates - Investing.com UK

Mar 17, 2025
pulisher
Mar 15, 2025

SANGAMO THERAPEUTICS Earnings Preview: Recent $SGMO Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 15, 2025
pulisher
Mar 13, 2025

SBI Securities Co. Ltd. Invests $28,000 in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference - Zenopa

Mar 12, 2025
pulisher
Mar 09, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript - MSN

Mar 09, 2025
pulisher
Mar 07, 2025

Sangamo Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 - WICZ

Mar 06, 2025
pulisher
Mar 04, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough - Simply Wall St

Mar 04, 2025
pulisher
Mar 02, 2025

10 Promising Biotech Stocks to Invest in (March 2025) - Securities.io

Mar 02, 2025
pulisher
Feb 28, 2025

Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89% - Yahoo Finance

Feb 28, 2025
pulisher
Feb 23, 2025

Head-To-Head Comparison: Sangamo Therapeutics (NASDAQ:SGMO) versus Novavax (NASDAQ:NVAX) - Defense World

Feb 23, 2025
pulisher
Feb 13, 2025

Isaralgagene civaparvovec (ST-920) for Fabry disease – Fabry... - Fabry Disease News

Feb 13, 2025
pulisher
Feb 11, 2025

Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit (NASDAQ:SGMO) - Seeking Alpha

Feb 11, 2025
pulisher
Feb 07, 2025

Sangamo reports positive Fabry disease gene therapy results By Investing.com - Investing.com Nigeria

Feb 07, 2025
pulisher
Feb 06, 2025

Sangamo reports positive Fabry disease gene therapy results - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Sangamo reports updated data for gene therapy candidate ST-920 - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile - BioSpace

Feb 06, 2025
pulisher
Feb 06, 2025

Sangamo Therapeutics (NASDAQ:SGMO) delivers shareholders stellar 160% return over 1 year, surging 12% in the last week alone - Simply Wall St

Feb 06, 2025
pulisher
Feb 04, 2025

Golden State Equity Partners Has $332,000 Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat

Feb 04, 2025

Sangamo Therapeutics Inc (SGMO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):